A Randomized, Double-blind, Placebo-controlled Trial of AC-701 for Treatment of Skin Rash in Subjects With EGFR Inhibitor Therapy
Latest Information Update: 28 Apr 2022
At a glance
- Drugs AC 701 (Primary)
- Indications Exanthema
- Focus Adverse reactions
- Sponsors TWi Biotechnology
Most Recent Events
- 25 Apr 2022 Status changed from recruiting to completed.
- 04 Feb 2020 New trial record